Mohamed, Mohamed S <br/><br/>
Sofosbuvir and daclatasvir plus ribavirin treatment improve liver function parameters and clinical outcomes in Egyptian chronic hepatitis C patients.  [electronic resource] 

 -  European journal of gastroenterology & hepatology  Dec 2017 
 - 1368-1372 p.  digital 
<br/><br/> Publication Type: Journal Article; Observational Study 
<br/><br/><label>ISSN: </label>1473-5687 
<br/><br/><label>Standard No.: </label>10.1097/MEG.0000000000000963  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Alanine Transaminase--blood<br/>Antiviral Agents--therapeutic use<br/>Aspartate Aminotransferases--blood<br/>Bilirubin--blood<br/>Carbamates<br/>Drug Therapy, Combination<br/>Egypt<br/>End Stage Liver Disease--physiopathology<br/>Female<br/>Hepatitis C, Chronic--blood<br/>Humans<br/>Imidazoles--therapeutic use<br/>International Normalized Ratio<br/>Male<br/>Middle Aged<br/>Platelet Count<br/>Prospective Studies<br/>Pyrrolidines<br/>Ribavirin--therapeutic use<br/>Serum Albumin--metabolism<br/>Severity of Illness Index<br/>Sofosbuvir--therapeutic use<br/>Sustained Virologic Response<br/>Valine--analogs & derivatives